TECHNOLOGY

TECHNOLOGY

TECHNOLOGY

Introducing the basic technology for which RegeNephro has applied for a patent.

Nephron progenitor cells (NPCs) (core seeds technology)

The team of our chief scientific advisor has developed an intermediate mesoderm that faithfully reproduces the developmental process from pluripotent stem cells and a highly efficient method for inducing differentiation of intermediate mesoderm into NPCs. They also showed that cell therapy with NPCs is effective in several mouse models of renal disease. Currently, a patent is pending for the differentiation induction method. According...

Erythropoietin (EPO) -producing cells

The team of our chief scientific advisor has succeeded in inducing the first differentiation of pluripotent stem cells that produce EPO. They also showed that the cell transplantation is effective in treating renal anemia in a mouse model. It is expected as a new therapy for renal anemia that enables physiological control. A patent has been obtained for the method of inducing erythropoietin-producing...

Ureteral blast cells

The team of our chief scientific advisor has succeeded in inducing highly efficient differentiation of ureteral embryonic tissue from pluripotent stem cells for the first time. Ureter buds are fetal precursors that derive the lower urinary tract from the collecting duct to part of the bladder. Together with nephron progenitor cells, it will be a basic technology for renal organ reconstruction. Currently, a...

Expansion culture method for nephron progenitor cells (NPCs)

The team of our chief scientific advisor has developed a culture method that maintains the optimal undifferentiated state of NPCs and expands them more than 100 times. This dramatically increases productivity and enables significant manufacturing cost reductions.    

Concentration and purification of nephron progenitor cells (NPCs)

The team of our chief scientific advisor have identified cell surface markers that are specific to NPCs. By using this surface marker, they also succeeded in removing undifferentiated cells that have potential for causing malignancy. Currently, a patent is pending for the enrichment and purification technology.

Technology for producing renal organoids

The team of our chief scientific advisor has succeeded in producing renal organoids including glomeruli and renal tubules from human iPS cell-derived nephron progenitor cells. This technology will enable to evaluate the presence or absence of side effects of a new candidate drugs on the kidney, and will also enable to analyze pathological conditions using patient-derived disease-specific iPS cells and to find more...